

OMB No. 0651-0011 (exp. 4/94)

PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Novartis Corporation (formerly Ciba-Geigy Corporation)

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: CIBA Vision Corporation
Internal Address: _____

Street Address: 11460 Johns Creek Parkway

City: Duluth State: GA ZIP: 30097-1556

Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other _____

Execution Date: November 6, 2000

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No.(s) _____ B. Patent No.(s) 5,362,767

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Thomas Hoxie
Internal Address: Novartis Corporation
Patent and Trademark Dept.
Street Address: 564 Morris Avenue
City: Summit State: NJ ZIP: 07901-1027

6. Total number of applications and patents involved: 1
7. Total fee (37 CFR 3.41) \$ 40
 Enclosed
 Authorized to be charged to deposit account and any other additional fees required.
8. Deposit account number:
19-0134 (in the name of Novartis Corporation)
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Melvyn M. Kassenoff Melvyn M. Kassenoff November 6, 2000
Name of Person Signing Signature Date
Reg. No. 26,389

Certificate of mailing on reverse side

Total number of pages including cover sheet, attachments, and document: 2

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

ASSIGNMENT

Whereas, Novartis Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, and Max-Planck-Gesellschaft zur Förd. d. Wissensch., Munich, Germany, are jointly the assignees and legal owners of the entire right, title and interest in United States Patent 5,362,767;

Whereas, Novartis Corporation was formerly known as Ciba-Geigy Corporation, the change of name having been recorded in the Patent and Trademark Office on October 13, 1998 (Reel 9507, Frames 0112-0114); and

Whereas, Novartis Corporation wishes to assign its entire interest in United States Patent 5,362,767 to CIBA Vision Corporation, 11460 Johns Creek Parkway, Duluth, GA 30097-1556, a corporation of Delaware, and said CIBA Vision Corporation wishes to acquire Novartis Corporation's interest in said patent.

Now, therefore, Novartis Corporation hereby assigns to CIBA Vision Corporation and its successors and assigns its entire right, title and interest in (a) United States Patent 5,362,767, (b) any and all applications for reissues of said patent, (c) any and all reissues of said patent that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Corporation to CIBA Vision Corporation together with the right, title and interest currently held by Max-Planck-Gesellschaft zur Förd. d. Wissensch. constituting the entire right, title and interest in said patents (including reissue patents), extensions and reexamination certificates.

In witness whereof, Novartis Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 6th day of November 2000.

Novartis Corporation



Thomas Hoxie
Vice-President